Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.

BACKGROUND Decisions on the timing and extent of vaccination against pandemic (H1N1) 2009 virus are complex. OBJECTIVE To estimate the effectiveness and cost-effectiveness of pandemic influenza (H1N1) vaccination under different scenarios in October or November 2009. DESIGN Compartmental epidemic model in conjunction with a Markov model of disease progression. DATA SOURCES Literature and expert opinion. TARGET POPULATION Residents of a major U.S. metropolitan city with a population of 8.3 million. TIME HORIZON Lifetime. PERSPECTIVE Societal. INTERVENTIONS Vaccination in mid-October or mid-November 2009. OUTCOME MEASURES Infections and deaths averted, costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness. RESULTS OF BASE-CASE ANALYSIS Assuming each primary infection causes 1.5 secondary infections, vaccinating 40% of the population in October or November would be cost-saving. Vaccination in October would avert 2051 deaths, gain 69 679 QALYs, and save $469 million compared with no vaccination; vaccination in November would avert 1468 deaths, gain 49 422 QALYs, and save $302 million. RESULTS OF SENSITIVITY ANALYSIS Vaccination is even more cost-saving if longer incubation periods, lower rates of infectiousness, or increased implementation of nonpharmaceutical interventions delay time to the peak of the pandemic. Vaccination saves fewer lives and is less cost-effective if the epidemic peaks earlier than mid-October. LIMITATIONS The model assumed homogenous mixing of case-patients and contacts; heterogeneous mixing would result in faster initial spread, followed by slower spread. Additional costs and savings not included in the model would make vaccination more cost-saving. CONCLUSION Earlier vaccination against pandemic (H1N1) 2009 prevents more deaths and is more cost-saving. Complete population coverage is not necessary to reduce the viral reproductive rate sufficiently to help shorten the pandemic. PRIMARY FUNDING SOURCE Agency for Healthcare Research and Quality and National Institute on Drug Abuse.